Stryker Corporation $SYK Shares Sold by KBC Group NV

KBC Group NV cut its stake in Stryker Corporation (NYSE:SYK) by 16.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 321,950 shares of the medical technology company’s stock after selling 64,390 shares during the period. KBC Group NV’s holdings in Stryker were worth $127,373,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new position in Stryker during the second quarter worth approximately $26,000. Sachetta LLC lifted its position in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the period. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd purchased a new position in Stryker during the 1st quarter worth $37,000. Finally, Solstein Capital LLC acquired a new position in shares of Stryker during the second quarter worth about $43,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 2.4%

Shares of NYSE SYK opened at $363.68 on Wednesday. The firm has a market cap of $139.08 billion, a P/E ratio of 48.17, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The firm’s 50 day moving average price is $373.39 and its 200 day moving average price is $381.33.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter last year, the firm earned $2.87 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 520,500 shares of company stock valued at $184,803,065. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SYK shares. UBS Group set a $408.00 price objective on Stryker in a report on Monday, October 13th. Rothschild & Co Redburn began coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. BTIG Research raised their target price on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average target price of $433.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.